期刊文献+

miR-29c-5p负性调控CPEB4对肾透明细胞癌细胞增殖、迁移的影响 被引量:1

The effect of miR-29c-5p on the proliferation and migration of clear cell renal carcinoma cells by negatively regulating CPEB4
下载PDF
导出
摘要 目的探讨miR-29c-5p对胞质多聚腺苷酸化原件结合蛋白4(CPEB4)的负性调控作用,以及对肾透明细胞癌Caki-1细胞增殖、迁移的影响。方法采用Lipofectamine TM 2000将miR-NC(miR-NC组)、miR-29c-5p mimics(miR-29c-5p mimics组)、miR-29c-5p inhibitor(miR-29c-5p inhibitor组)、miR-29c-5p inhibitor+si-CPEB4转染(si-CPEB4+miR-29c-5p inhibitor组)转染至Caki-1细胞。采用MTT法和Transwell实验检测各组细胞增殖和迁移活性的影响,采用实时荧光定量PCR(QPCR)和Western blotting检测各组miR-29c-5p、CPEB4 mRNA和蛋白的表达水平。结果miR-29c-5p mimics组细胞的增殖和迁移活性明显低于miR-NC组(P<0.05);而miR-29c-5p inhibitor组细胞的增殖和迁移活性明显高于miR-NC组(P<0.05)。miR-29c-5p mimics组CPEB4 mRNA和蛋白的表达水平明显低于miR-NC组和miR-29c-5p inhibitor组,差异具有统计学意义(P<0.05);miR-29c-5p inhibitor组CPEB4 mRNA和蛋白的表达量明显高于miR-NC组和miR-29c-5p mimics组,差异具有统计学意义(P<0.05)。沉默CPEB4基因表达后,miR-29c-5p inhibitor组miR-29c-5p表达水平明显上调,差异具有统计学意义(P<0.05)。与miR-29c-5p inhibitor组比较,si-CPEB4+miR-29c-5p inhibitor组细胞的增殖和迁移活性明显降低,差异具有统计学意义(P<0.05)。结论miR-29c-5p可负性调控CPEB4的表达,从而抑制肾透明细胞癌的增殖和迁移活性。 Objective To investigate the negative regulation of miR-29c-5p on cytoplasmic polyadenylation primitive binding protein 4(CPEB4)and its effect on the proliferation and migration of renal clear cell carcinoma Caki-1 cells.Methods miR-NC(miR-NC group),miR-29c-5p mimics(miR-29c-5p mimics group),miR-29c-5p inhibitor(miR-29c-5p inhibitor group)and miR-29c-5p inhibitor+si-CPEB4(si-CPEB4+miR-29c-5p inhibitor group)were transfected into Caki-1 cells by Lipofectamine TM 2000.MTT assay and Transwell assay were used to detect the effects of cell proliferation and migration activity in each group.Real-time fluorescence quantitative PCR(QPCR)and Western blotting were used to detect the expression levels of miR-29c-5p,CPEB4 mRNA and CPEB4 protein in each group.Results The proliferation and migration activity of the cells in the miR-29c-5p mimics group was significantly lower than that in the miR-NC group(P<0.05);while the proliferation and migration activity of cells in the miR-29c-5p inhibitor group was significantly higher than that in the miR-NC group(P<0.05).The proliferation and migration activity of cells in the miR-29c-5p inhibitor group was significantly higher than that in the miR-NC group(P<0.05).The expression levels of CPEB4 in the miR-29c-5p mimics group were significantly lower than those in the miR-NC group and the miR-29c-5p inhibitor group(P<0.05).The expression levels of CPEB4 in the miR-29c-5p inhibitor group were significantly higher than those in the miR-NC group and the miR-29c-5p mimics group(P<0.05).After silencing the expression of CPEB4 gene,the expression of miR-29c-5p of miR-29c-5p inhibitor group increased significantly(P<0.05).Compared with the miR-29c-5p inhibitor group,the proliferation and migration activity of cells in the si-CPEB4+miR-29c-5p inhibitor group decreased significantly(P<0.05).Conclusion There are significant evidences that miR-29c-5p could inhibit the proliferation of clear cell renal cell carcinoma by down-regulation CPEB4 expression.
作者 许治华 王东 王晋 XU Zhihua;WANG Dong;Wang Jin(Clinical Medical College of Southwest Medical University,Luzhou 646000,China)
出处 《临床肿瘤学杂志》 CAS 北大核心 2019年第9期785-790,共6页 Chinese Clinical Oncology
关键词 肾透明细胞癌 miR-29c-5p 胞质多聚腺苷酸化原件结合蛋白4 增殖 迁移 Clear cell renal cell carcinoma(ccRCC) miR-29c-5p Cytoplasmic poly-adenylation element binding protein 4(CPEB4) Proliferation Migration
  • 相关文献

参考文献7

二级参考文献105

  • 1International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2008[EB/ OL]. 2010. [ 2013-11-15]. http://globocan, iare. fr/.
  • 2COPPIN C, LE L, PORZSOLT F, et al. Targeted therapy for advanced renal cell Carcinoma[J]. Cochrane Database Syst Rev, 2008,16(2) :CD006017.
  • 3MOTZER RJ, HUTSON TE, TOMCZAK P, et al. Overall sur viral and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin 0ncol,2009, 27(22): 3584-3590.
  • 4MCDERMOTT DF, REGAN MM, CLARK JI, et al. Random- ized phase Ⅲ trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal car- cinoma[J]. J Clin Oncol,2005 ,23(1) :133-141.
  • 5MOTZER RJ, BACIK J, SCHWARTZ LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2004,22(3) : 454-463.
  • 6FLANIGAN RC, MICKISCH G, SYLVESTER R, et al. Cy- toreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J]. J Urol,2004, 171(3): 1071-1076.
  • 7COLEMAN RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies[J]. Cancer Treat Rev, 2001,27(3) : 165-176.
  • 8LJUNGBERG B, COWAN NC, HANBURY DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update[J]. Eur Urol,2010,58(3) :398-406.
  • 9MOTZER RJ, MICHAELSON MD, REDMAN BG, et al. Ac- tivity of SUl1248, a multitargeted inhibitor of vascular endothe- lial growth factor receptor and platelet-derived rowth factor re- ceptor in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2006, 24(1) :16-24.
  • 10RINI BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma[J]. Cancer, 2009, 115: 2306- 2312.

共引文献53

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部